Italia - italiano - Ministero della Salute

natur srl -

Unión Europea - italiano - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - policitemia vera - immunostimolanti, - besremi è indicato come monoterapia negli adulti per il trattamento della policitemia vera, senza sintomatico splenomegalia.

Suiza - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - fampridinum - retardtabletten - fampridinum 10 mg, cellulosum microcristallinum, hypromellosum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 400, titanii dioxidum, pro compresso obducto. - multiple sklerose - synthetika

Unión Europea - italiano - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ricombinante del virus della stomatite vescicolare (ceppo indiana) con l'eliminazione della glicoproteina busta, sostituito con lo zaire ebolavirus (ceppo kikwit 1995) glicoproteina di superficie - febbre emorragica di ebola - vaccini - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. l'uso di ervebo dovrebbe essere in conformità con le raccomandazioni ufficiali.

Suiza - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

orpha swiss gmbh - ropeginterferonum alfa-2b - soluzione iniettabile in penna preriempita - ropeginterferonum alfa-2b 250 µg, natrii chloridum, natrii acetas, acidum aceticum glaciale, alcohol benzylicus 5 mg, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml corresp. natrium 1.8 mg. - polycythaemia vera - biotechnologika

Suiza - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

orpha swiss gmbh - ropeginterferonum alfa-2b - soluzione iniettabile in penna preriempita - ropeginterferonum alfa-2b 500 µg, natrii chloridum, natrii acetas, acidum aceticum glaciale, alcohol benzylicus 5 mg, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml corresp. natrium 1.8 mg. - polycythaemia vera - biotechnologika

Unión Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - fampridine - sclerosi multipla - altri farmaci sul sistema nervoso - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).

Suiza - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - rvsvdeltag-zebov-gp vivus attenuatum - soluzione iniettabile - rvsvdeltag-zebov-gp vivus attenuatum >7.2 mio u., trometamolum, albuminum humanum, aqua ad iniectabile, q.s. ad solutionem pro 1 ml. - ervebo ist indiziert für die aktive immunisierung von personen ab 18 jahren zum schutz vor der ebola-viruskrankheit (evd [ebola virus disease]), die durch das zaire-ebola-virus verursacht wird - vaccini

Unión Europea - italiano - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus eritematoso, sistemico - immunosoppressori - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Unión Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.